

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

CLAIMS

100-7730

1. An improved method of treating inflammatory or obstructive airways disease in a human subject in need thereof, which method comprises administering to said subject a selective β_2 sympathomimetic bronchodilator drug predominantly in the form of its BRONCHODILATOR ENANTIOMER.
2. A method according to claim 1 of treating inflammatory or obstructive airways disease with the avoidance, amelioration or restriction of occurrence of side effect deleterious to the airways.
3. A method according to claim 1 of treating inflammatory or obstructive airways disease with the avoidance, amelioration or restriction of exacerbation of basal disease status or compromise or deterioration of lung function.
4. A method according to claim 1 which additionally comprises administration of an anti-asthmatically effective amount of ketotifen.
5. A method according to claim 1 which comprises administering a selective β_2 sympathomimetic drug in pure or substantially pure form.
6. A method according to claim 1 wherein said selective β_2 sympathomimetic bronchodilator drug is selected from the group consisting of terbutaline, albuterol, fenoterol, hexoprenaline, rimiterol, isoetharine, orciprenaline, reproterol, clenbuterol, procaterol, carbuterol, tolobuterol, pirbuterol, bitolterol, formoterol, bambuterol and salmeterol.
7. A pharmaceutical composition comprising a selective β_2 sympathomimetic bronchodilator drug predominantly in the

form of its BRONCHODILATOR ENANTIOMER together with a pharmaceutically acceptable diluent or carrier therefor.

8. A pharmaceutical composition according to claim 7 comprising BRONCHODILATOR ENANTIOMER of a selective β_2 sympathomimatic bronchodilator drug in pure or substantially pure form.
9. A pharmaceutical composition according to claim 7 wherein said selective β_2 sympathomimatic bronchodilator drug is selected from the group consisting of terbutaline, albuterol, fenoterol, hexoprenaline, rimiterol, isoetharine, orciprenaline, reproterol, clenbuterol, procaterol, carbuterol, tolobuterol, pirbuterol, bitolterol, formoterol, bambuterol and salmeterol.
10. A pharmaceutical composition according to claim 7 in a form permitting, enabling or adapted for administration via the pulmonary route.